These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30507575)

  • 41. Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.
    Ten Kate M; Barkhof F; Boccardi M; Visser PJ; Jack CR; Lovblad KO; Frisoni GB; Scheltens P;
    Neurobiol Aging; 2017 Apr; 52():167-182.e1. PubMed ID: 28317647
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnostic differentiation of mild cognitive impairment due to Alzheimer's disease using a hippocampus-dependent test of spatial memory.
    Moodley K; Minati L; Contarino V; Prioni S; Wood R; Cooper R; D'Incerti L; Tagliavini F; Chan D
    Hippocampus; 2015 Aug; 25(8):939-51. PubMed ID: 25605659
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment.
    Baldeiras I; Santana I; Leitão MJ; Gens H; Pascoal R; Tábuas-Pereira M; Beato-Coelho J; Duro D; Almeida MR; Oliveira CR
    Alzheimers Res Ther; 2018 Mar; 10(1):33. PubMed ID: 29558986
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Auditory Event-related Potentials in Mild Cognitive Impairment and Alzheimer's Disease.
    Morrison C; Rabipour S; Knoefel F; Sheppard C; Taler V
    Curr Alzheimer Res; 2018; 15(8):702-715. PubMed ID: 29359668
    [TBL] [Abstract][Full Text] [Related]  

  • 45. On the personal utility of Alzheimer's disease-related biomarker testing in the research context.
    Bunnik EM; Richard E; Milne R; Schermer MHN
    J Med Ethics; 2018 Dec; 44(12):830-834. PubMed ID: 30154216
    [TBL] [Abstract][Full Text] [Related]  

  • 46. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
    Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
    Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease.
    Parnetti L; Chiasserini D
    Biomark Med; 2011 Aug; 5(4):479-84. PubMed ID: 21861669
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predicting Progression From Mild Cognitive Impairment to Alzheimer's Disease Using Autoregressive Modelling of Longitudinal and Multimodal Biomarkers.
    Minhas S; Khanum A; Riaz F; Khan SA; Alvi A
    IEEE J Biomed Health Inform; 2018 May; 22(3):818-825. PubMed ID: 28534796
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neuropsychological Measures that Predict Progression from Mild Cognitive Impairment to Alzheimer's type dementia in Older Adults: a Systematic Review and Meta-Analysis.
    Belleville S; Fouquet C; Hudon C; Zomahoun HTV; Croteau J;
    Neuropsychol Rev; 2017 Dec; 27(4):328-353. PubMed ID: 29019061
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Biomarkers in Alzheimer's disease].
    García-Ribas G; López-Sendón Moreno JL; García-Caldentey J
    Rev Neurol; 2014 Apr; 58(7):308-17. PubMed ID: 24677154
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Connected speech and language in mild cognitive impairment and Alzheimer's disease: A review of picture description tasks.
    Mueller KD; Hermann B; Mecollari J; Turkstra LS
    J Clin Exp Neuropsychol; 2018 Nov; 40(9):917-939. PubMed ID: 29669461
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot.
    Hampel H; Lista S; Khachaturian ZS
    Alzheimers Dement; 2012 Jul; 8(4):312-36. PubMed ID: 22748938
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Method to Differentiate Mild Cognitive Impairment and Alzheimer in MR Images using Eigen Value Descriptors.
    Anandh KR; Sujatha CM; Ramakrishnan S
    J Med Syst; 2016 Jan; 40(1):25. PubMed ID: 26547845
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.
    Mattsson N; Lönneborg A; Boccardi M; Blennow K; Hansson O;
    Neurobiol Aging; 2017 Apr; 52():196-213. PubMed ID: 28317649
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients.
    Di Domenico F; Pupo G; Giraldo E; Badìa MC; Monllor P; Lloret A; Schininà ME; Giorgi A; Cini C; Tramutola A; Butterfield DA; Viña J; Perluigi M
    Free Radic Biol Med; 2016 Feb; 91():1-9. PubMed ID: 26675344
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emerging biomarkers and screening for cognitive frailty.
    Ruan Q; D'Onofrio G; Sancarlo D; Greco A; Lozupone M; Seripa D; Panza F; Yu Z
    Aging Clin Exp Res; 2017 Dec; 29(6):1075-1086. PubMed ID: 28260159
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia.
    Davis M; O Connell T; Johnson S; Cline S; Merikle E; Martenyi F; Simpson K
    Curr Alzheimer Res; 2018; 15(8):777-788. PubMed ID: 29357799
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neural Dynamics of Multiple Object Processing in Mild Cognitive Impairment and Alzheimer's Disease: Future Early Diagnostic Biomarkers?
    Bagattini C; Mazza V; Panizza L; Ferrari C; Bonomini C; Brignani D
    J Alzheimers Dis; 2017; 59(2):643-654. PubMed ID: 28671112
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Retinal pathology as biomarker for cognitive impairment and Alzheimer's disease.
    Ikram MK; Cheung CY; Wong TY; Chen CP
    J Neurol Neurosurg Psychiatry; 2012 Sep; 83(9):917-22. PubMed ID: 22733082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.